Eugene Spier is a pioneering force in the field of molecular diagnostics, currently serving as the Founder of UniTaq Bio. With a robust background in designing, quality controlling, and multiplexing quantitative PCR (qPCR) tests, Eugene has positioned himself at the forefront of innovative diagnostic solutions...
Eugene Spier is a pioneering force in the field of molecular diagnostics, currently serving as the Founder of UniTaq Bio. With a robust background in designing, quality controlling, and multiplexing quantitative PCR (qPCR) tests, Eugene has positioned himself at the forefront of innovative diagnostic solutions for both clinical and research use. His expertise extends beyond the technical aspects of qPCR; he is also a trusted consultant, providing invaluable insights and strategic guidance on PCR methodologies and diagnostic applications to a diverse clientele.
At UniTaq Bio, Eugene has spearheaded the development of next-generation qPCR assays that enhance the detection of nucleic acids, significantly improving the accuracy and efficiency of diagnostic processes. The company’s intellectual property portfolio is impressive, holding three US patents and one pending European Patent Office (EPO) patent. These patents encompass groundbreaking methods and compositions for universal nucleic acid detection and the use of blocked and universal primers in PCR, reflecting Eugene's commitment to advancing the field of biotechnology.
In addition to his work on qPCR assays, Eugene has developed software tools tailored for qPCR applications, which are available for licensing. These tools not only streamline the analysis process but also empower researchers and clinicians to achieve more reliable results. His skills in bioinformatics, computational biology, and R&D are instrumental in driving UniTaq Bio's mission to innovate and enhance the life sciences landscape. Through his leadership and vision, Eugene Spier continues to make significant contributions to the biotechnology sector, fostering advancements that will shape the future of diagnostics and research.
